Taking into consideration the synergistic effects of PDE4 and PDE3 inhibitors and beneficial effects of dual PDE3/4 inhibitors in the treatment of respiratory diseases [83,84,85], it seems likely that simultaneous inhibition of the PDE7 and PDE3 families could also be a promising therapeutic target. The gene discussed is PDE4A; the disease is respiratory system disorder.